Zepbound vs Mounjaro: Same Drug, Different Names Explained

Zepbound and Mounjaro are the same drug

This is the most important thing to understand: Zepbound and Mounjaro are the exact same medication. Same molecule (tirzepatide). Same manufacturer (Eli Lilly). Same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg). Same injection pen. Same mechanism of action. Same side effects. If you put both medications under a microscope, you would not be able to tell them apart, because there is nothing to tell apart.

Tirzepatide is a dual GLP-1 and GIP receptor agonist. It activates two hormonal pathways simultaneously to reduce appetite, slow gastric emptying, improve insulin sensitivity, and promote fat metabolism. Whether the label on the pen says Zepbound or Mounjaro, the molecule doing the work inside your body is identical.

Why does the same drug have two names?

This is standard pharmaceutical practice, not a trick. When a drug company develops a molecule that treats multiple conditions, they often seek separate FDA approvals for each indication. Each approval gets its own brand name, its own marketing, and its own pricing and insurance negotiation.

Mounjaro was approved by the FDA in May 2022 for the treatment of type 2 diabetes. It was the first tirzepatide product to reach the market, and its clinical development focused on glycemic control as the primary endpoint.

Zepbound was approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity. Its clinical development, the SURMOUNT trial program, focused on body weight reduction as the primary endpoint.

The split allows Eli Lilly to position each product differently in the market. Mounjaro competes with Ozempic in the diabetes space. Zepbound competes with Wegovy in the weight management space. Different payer negotiations, different copay programs, different marketing strategies — but the same molecule.

The insurance difference: this is what actually matters

Since the molecule is identical, the practical difference between Zepbound and Mounjaro comes down to which one your insurance will cover — and that depends on your diagnosis.

Mounjaro and insurance: Diabetes medications have better insurance coverage in general. Most major insurance plans include GLP-1 agonists on their formulary for type 2 diabetes. If you have a type 2 diabetes diagnosis, Mounjaro is more likely to be covered, though prior authorization is often required and some plans prefer Ozempic as the first-line GLP-1.

Zepbound and insurance:Weight management medications have historically poor insurance coverage. Many plans explicitly exclude anti-obesity medications from their formulary. Coverage is improving — particularly among employer-sponsored plans and some Medicare Part D plans — but Zepbound faces more coverage barriers than Mounjaro. Eli Lilly has launched aggressive savings programs for Zepbound, but these typically have eligibility restrictions and expiration dates.

The off-label reality: Many physicians prescribe Mounjaro off-label for weight management, particularly if the patient also has pre-diabetes, insulin resistance, or metabolic syndrome that could justify the diabetes indication. Off-label prescribing is legal and common, but insurance coverage for off-label use is inconsistent.

Cost comparison

At list prices without insurance, the cost difference between the two is negligible — roughly $36 per month. The meaningful cost difference comes from insurance coverage, which is driven entirely by your diagnosis and your plan's formulary.

Which should you ask your physician for?

Since the medication is identical, the prescription decision should be driven by your diagnosis and insurance situation, not by a preference for one brand name over the other.

If you have type 2 diabetes: Ask for Mounjaro. It is FDA-indicated for your condition and is more likely to be covered by your insurance. You will get the weight loss benefit regardless of which indication is on the prescription.

If your primary goal is weight management without diabetes: Zepbound is the FDA-indicated option. Check with your insurance first. If Zepbound is not covered, your physician may explore whether your metabolic profile supports a Mounjaro prescription based on pre-diabetes or insulin resistance.

If you are paying cash: It genuinely does not matter which brand name is on the prescription. The molecule is the same and the list prices are nearly identical. But if you are paying cash, you should strongly consider the compounded alternative.

The compounded alternative

For patients paying out of pocket, the most important comparison is not Zepbound vs Mounjaro — it is branded tirzepatide vs compounded tirzepatide. Compounded tirzepatide from a licensed 503A or 503B pharmacy contains the same active molecule at the same doses, typically at $200 to $400 per month versus $1,000+ for the branded versions.

The compounded market does not distinguish between Zepbound and Mounjaro because the underlying molecule is the same. A compounding pharmacy produces tirzepatide — period. The FDA indication on the branded product is irrelevant to the compounded version.

Important caveats: compounded medications are not FDA-approved products. Quality varies between pharmacies. You need a physician who understands compounded GLP-1s and works with reputable pharmacies. For a comprehensive breakdown of compounded options and how to find the best prices, see our cheapest GLP-1 guide.

Frequently asked questions

Are Zepbound and Mounjaro the same drug?

Yes. Both are tirzepatide manufactured by Eli Lilly. Same molecule, same doses, same mechanism. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

Why does tirzepatide have two brand names?

Pharmaceutical companies routinely market the same molecule under different brand names for different conditions. Each FDA indication has its own regulatory pathway, pricing, and insurance negotiation. Lilly markets Mounjaro to endocrinologists for diabetes and Zepbound to obesity medicine specialists for weight management.

Which is cheaper, Zepbound or Mounjaro?

At list price, nearly identical (Mounjaro ~$1,023/mo, Zepbound ~$1,059/mo). The real cost difference depends on insurance. Mounjaro is more likely to be covered for patients with diabetes. Compounded tirzepatide at $200 to $400/mo is the cheapest option for cash-pay patients. See our cheapest GLP-1 guide.

Can my doctor prescribe Mounjaro for weight loss?

Yes. Off-label prescribing is legal and common. Many physicians prescribe Mounjaro for weight management, particularly if the patient also has insulin resistance or pre-diabetes. However, insurance may not cover Mounjaro when prescribed off-label for weight loss.

Should I choose Zepbound or Mounjaro?

Your physician should decide based on your diagnosis and insurance. If you have type 2 diabetes, Mounjaro. If weight management is your primary goal, Zepbound. If you are paying cash, it does not matter — consider compounded tirzepatide instead. For a broader comparison of GLP-1 options, see our tirzepatide vs semaglutide comparison or learn about getting Mounjaro online.